Monospecific antibody against Bordetella pertussis Adenylate Cyclase protects from Pertussis

Anahtar Kelimeler:

-

Monospecific antibody against Bordetella pertussis Adenylate Cyclase protects from Pertussis

Objectives: Acellular pertussis vaccines has been largely accepted world-wide however, there are reports about limited antibody response against these vaccines suggesting that multiple antigens should be included in acellular vaccines to attain full protection. The aim of present study was to evaluate the role of Bordetella pertussis adenylate cyclase as a protective antigen. Materials and methods: Highly mono-specific antibody against adenylate cyclase (AC) was raised in rabbits using nitrocellulose bound adenylate cyclase and the specificity was assessed by immuoblotting. B.pertussis 18-323, was incubated with the mono-specific serum and without serum as a control. Mice were challenged intra-nasally and pathophysiolgical responses were recorded. Results: The production of B.pertussis adenylate cyclase monospecific antibody that successfully recognized on immunoblot and gave protection against fatality (p< 0.01) and lung consolidation (p <0.01). Mouse weight gain showed significant difference (p< 0.05). Conclusion: These preliminary results highlight the role of the B.pertussis adenylate cyclase as a potential pertussis vaccine candidate. B.pertussis AC exhibited significant protection against pertussis in murine model.

Keywords:

Pertussis; monospecific; antibody; passive-protection,

PDF

___

Preston NW. Pertussis today. In: Pathogenesis and Immunity in Pertussis (Eds. A.C Wardlaw and R.Parton) 1988; 108 John Wiley & Sons.
Cherry JD. Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clin Infect Dis 1999 ; 28 :S112-117.
Bettiol S, Thompson MJ, Roberts NW, Perera R, Heneghan CJ, Harnden A. Symptomatic treatment of the cough in whooping cough. Database Syst Rev. 2010 J; CD003257.
World Health Organization. Informal consultation on control of Pertussis with whole cell and acellular vaccines, Geneva 1988, (18-19 may).
WHO/IVB database 2011. http://www.who.int/immunization_ monitoring/diseases/Pertussis_coverage
Long SS, Welkon CJ, Clark JL. Wide spread silent transmis- sion of Pertussis in families: antibody correlates with infec- tion and symptomatology. J Infect Dis 1990; 161: 480-486.
Deen JL, Mink CA, Cherry JD, et al. Household contact study of Bordetella pertussis infections. Clin Infect Dis 1995; 21:1211-9.
Cherry J.D, Olin P . The science and fiction of Pertussis vac- cines. Pediatrics 1999; 104:1381-1384.
Edwards KM, Decker MD, Mortimer EA. Pertussis vaccines P.293-344 In Plotkin S.A and Orenstein W.A (ed), Vaccines 3rd ed. W.B Saunders Company, Philadelphia 1990; Pa.
Mastrantonio P, Spigaglia P, Van Oirschot H, et al. Antigenic variants in Bordetella pertussis strain isolated from vacci- nated and unvaccinated children Microbiol 1999 ;145: 2069- 2075.
Mooi F.R, Qiushui H, Van oirschot H, Mertsola J. Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect Immun 1999; 67: 3133-3134.
Mooi FR, Van oirschot H, Heuvelman K, Van der Heide HGJ, Gaastra W, Willems RJL Polymorphism in the Bordetella per- tussis virulence factors P.69/pertactin and pertussis toxin in Netherland: temporal trends and evidence for vaccine-driven evolution. Infect Immun 1998; 66: 670-675.
Rohani P, Drake JM. The decline and resurgence of pertussis in the US. Epidemics 2011; 3: 183-188.
Cherry JD, Heininger U, Richards DM, et al. Antibody Re- sponse Patterns to Bordetella pertussis Antigens in Vaccinat- ed (Primed) and Unvaccinated (Unprimed) Young Children with Pertussis Cl Vacc Immunol 2010;17: 741-747.
Farfel Z, Konen S, Wiertz E, Klampmuts R, Addy A, Hanski E. Antibodies to Bordetella pertussis adenylate cyclase are produced in man during pertussis infection and after vaccina- tion. J Med Microbiol 1990; 32:173-177.
Guiso N, Szatanik M, Rocancourt M. Protective activity of Bordetella adenylate cyclase and haemolysin against bacte- rial colonization. Microbiol. Pathol 1991; 11:423-431.
Brownlie RM, Coote JG, Parton R, Shultz JE, Rogel A, Hans- ki E. Cloning of the adenylate cyclase genetic determinant of Bordetella pertussis and its expression in E.coli and Borde- tella pertussis. Microbiol Pathol 1998;4:335-334..
Irons L.I, Ashworth L.A.E, Wilton-Smith P. Heterogeneity of the filamentous heamagglutinin of Bordetella pertussis stud- ies with monoclonal antibodies. J Gen Microbiol 1983; 129: 2769-2778.
Laemmli UK. Cleavage of structural protein during the as- sembly of the head of bacteriophage T4. Nature 1970;277: 680-685.
Knudsen AK. Proteins transferred to nitrocellulose for use as immunogen. Anal Biochem 1985; 147: 285-288.
Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76(9): 4350-4354.
Perkins FT, Sheffield WF, Outschoorn AS, Hamsley DA. An international collaborative study on the measurement of opacity of bacterial suspension. J Biol Stand 1973; 1:1-10.
Goodwin MS, Weiss AA. Adenylate cyclase toxin is critical for colonization and pertussis toxin is critical for lethal infection by Bordetella pertussis in infant mice. Infect Immun 1990; 58: 3445-3447.
Guiso N, Szatanik M, Alonso JM. Bordetella adenylate cy- clase is a virulence associated factor and an immunoprotec- tive antigen. Microb. Patho 1989 ;7(5):373-80.
Brézin C; Guiso N, Ladant ,D javadi-Ohaniance L, Me- gret F, Ignatius Onyeocha I, Alonso JM. Protective effects of anti-Bordetella pertussis adenylate cyclase antibod- ies against lethal respiratory infection of the mouse 2006; DOI:10.1111/j.1574-6968.1987.tb02302.x
Masure HR, Storm DR. Characterization of the bacterial cell associated calmodulin sensitive adenylate cyclase form Bor- detella pertussis. Biochemistry 1989; 28: 438-442.
Bellalou J, Sakamato H, Ladent D, Geoffroy C, Ullmann A. Deletion affecting hemolytic and toxic activities of Bordetella pertussis adenylate cyclase Infect. Immunology 1990;58: 3242-3247.
Gray MC, Jones FR, Kim T, Hewlet L. Newly secreted adenyl- ate cyclase toxin is responsible for intoxication of target cells by Bordetella pertussis. Mol Micbiol 2004; 53:1709-1719.
Crowcroft NS, Pebody RG. Recent developments in pertus- sis. Lancet 2006; 367:1926-1936.
Arciniega JL, Hewlett EL, Johnson FD. Human serologic response to envelope-associated proteins and adenylate cyclase toxin of Bordetella pertussis. J Infect Dis; 1991; 163:135-42.
Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three- component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 1997; 350:1569 1577.
Stehr K, Cherry JD, Heininger U, Schmitt-Grohe S, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics 1998; 101: 1-11.
Hormozi K, Parton R, Coote J. Adjuvant and protective prop- erties of native and recombinant Bordetella pertussis adenyl- ate cyclase toxin preparations in mice. FEMS Immunol Med Microbiol 1999; 23: 273-282.
Macdonald-Fyall, J, Xing D, Corbel M, Baillie S, Parton R, Coote J. Adjuvanticity of native and detoxified adenylate cy- clase toxin of Bordetella pertussis towards co-administered antigens. Vaccine 2004 ;22: 4270-4281.
Ross P, Lavelle C, Mills KH, Boyd A. Adenylate cyclase ttoxin from Bordetella pertussis synergizes with lipopolysaccharide to promote innate interleukin-10 production and enhances the induction of Th2 and regulatory T cells. Infect Immun 2004;72: 1568-1579.
Storsaeter, J, Hallander H, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after house- hold exposure to Bordetella pertussis. Vaccine 1998; 16:1907-1916.